|
|
|
02.04.26 - 22:03
|
FibroBiologics Announces Closing of $3 Million Public Offering (GlobeNewswire EN)
|
|
|
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $1.32 per share and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the “Stockholder Approval”) and will expire on the five-year anniversary of t...
|
|
|
01.04.26 - 02:03
|
FibroBiologics Announces Pricing of $3 Million Public Offering (GlobeNewswire EN)
|
|
|
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants will have an exercise price of $1.32 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the “Stockholder Approval”) and will expire on the five-year anniversary of the date of Sto...
|
|
|
31.03.26 - 22:18
|
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial (GlobeNewswire EN)
|
|
|
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the successful completion of manufacturing of the first batch of FibroBiologics' proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials. Manufactured in accordance with Food and Drug Administration's (FDA's) Good Manufacturing Practices (CGMP), the drug product will be released after it successfully passes all required safety and quality testing....
|
|
|
|
|
27.03.26 - 20:36
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 27.03.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 27.03.2026.
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.03.2026.
ISIN Name
CA98420Q3061 XORTX THERAPEUTICS
GB0009296665 VIDENDUM PLC LS-,20
GB00BF2P1260 SILVER BEAR RES LS-,001
JP3105040004 AIFUL CORP.
US31573L1052 FIBROBIOLOGICS INC....
|
|
|
27.03.26 - 16:54
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA98420Q3061 XORTX Therapeutics Inc. 27.03.2026 CA98420Q4051 XORTX Therapeutics Inc. 30.03.2026 Tausch 5:1
GB0009296665 Videndum PLC 27.03.2026 GB00BWGBNB23 Videndum PLC 30.03.2026 Tausch 200:1
US31573L1052 Fibrobiologics Inc. 27.03.2026 US31573L2043 Fibrobiologics Inc. 30.03.2026 Tausch 20:1...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 14:33
|
FibroBiologics to Present at the BIO Investment & Growth Summit (GlobeNewswire EN)
|
|
|
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
